Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
about
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapySynthesis of lysine methyltransferase inhibitorsProstate Cancer: Epigenetic Alterations, Risk Factors, and TherapyDiscovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation ApproachDOT1L safeguards cartilage homeostasis and protects against osteoarthritis.DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyondMLL leukemia induction by genome editing of human CD34+ hematopoietic cells.Dot1 histone methyltransferases share a distributive mechanism but have highly diverged catalytic properties.Decitabine: a promising epi-immunotherapeutic agent in solid tumors.Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.Epigenetic modifiers in normal and malignant hematopoiesis.Genetic mutations in epigenetic modifiers as therapeutic targets in acute myeloid leukemia.SAM/SAH Analogs as Versatile Tools for SAM-Dependent Methyltransferases.The upstreams and downstreams of H3K79 methylation by DOT1L.Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.In vitro mutagenic, antimutagenic, and antioxidant activities evaluation and biotransformation of some bioactive 4-substituted 1-(2-methoxyphenyl)piperazine derivatives.Safety issues of compounds acting on adenosinergic signalling.Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.Targeting human SET1/MLL family of proteins.Mechanistic investigations into the species differences in pinometostat clearance: impact of binding to alpha-1-acid glycoprotein and permeability-limited hepatic uptake.Metabolism and disposition of the DOT1L inhibitor, pinometostat (EPZ-5676), in rat, dog and human.Silencing of histone methyltransferase NSD3 reduces cell viability in osteosarcoma with induction of apoptosis.In Vitro Biotransformation, Safety, and Chemopreventive Action of Novel 8-Methoxy-Purine-2,6-Dione Derivatives.DOT1L and H3K79 Methylation in Transcription and Genomic Stability.Prominent role of histone lysine demethylases in cancer epigenetics and therapy
P2860
Q26746038-2C86EC06-F77A-487C-B9C3-A91100E22BF5Q26799953-5542FEC7-F4AA-42C4-97D6-B59DBF922E4DQ28073470-2EE4EEE7-A37E-420B-A6AF-282525D02BE1Q30392269-2C99B432-93A5-4CC0-9B55-5CF94E41B1EBQ33827165-060DFCFC-4FAC-4074-868D-6B86CE31BF6BQ35329614-E58E33C7-8AB7-41C5-A941-429CE72FB88EQ35967446-A732746E-4C53-4E9F-8113-FF301A1F918BQ36115756-D2E2DCF3-C3ED-44CB-B8E2-3E4A1E543420Q36293950-6BD30E2F-03A0-46C9-9739-AA03E53D12D1Q38314204-4678444B-5AF5-4990-9BBD-46FB87F9B701Q38435352-E41D269E-F7AB-435C-AA1A-224B5855F9AFQ38459868-F7E235EE-35BF-4C73-9BAF-424BBC2FCDAFQ38509706-8320EBD0-AFFC-4F8F-B0BF-70072BFF689FQ38625953-A4C778FD-3492-4045-96D4-0DE8AF9C5BD9Q38686217-A213A691-669E-4186-A2BD-C474AA8556A3Q38758820-25C03334-89AE-40C6-87E4-60A1C186EB9BQ38838563-B30F6E8C-E0BB-4E9D-97BA-2B7156043F03Q38843185-48261F3C-C8A7-48B5-B4D0-826F74FE57BAQ38946966-CD36DB46-1F6C-4000-870A-E76F1C34E4CAQ38979643-A05F062F-B130-4BD3-81A2-16AEF52BA818Q39782124-284D82AF-9441-4D0F-97A5-CF210B0AFF78Q46626956-0CB080E5-5094-4D5D-B3D6-6CCFDC78D0B5Q47681326-D55DA6CF-1BB1-40BA-BFF9-1B5A8E5D27BCQ48262358-5E7F6798-5C87-46DA-892B-14791D0F2851Q52729540-5C24C770-B750-4CCC-BDAB-3D24B8164787Q57826141-624CC995-B80D-4D09-ADD9-7C343FFEBB04
P2860
Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Nonclinical pharmacokinetics a ...... e methyltransferase inhibitor.
@en
Nonclinical pharmacokinetics a ...... e methyltransferase inhibitor.
@nl
type
label
Nonclinical pharmacokinetics a ...... e methyltransferase inhibitor.
@en
Nonclinical pharmacokinetics a ...... e methyltransferase inhibitor.
@nl
prefLabel
Nonclinical pharmacokinetics a ...... e methyltransferase inhibitor.
@en
Nonclinical pharmacokinetics a ...... e methyltransferase inhibitor.
@nl
P2093
P2860
P356
P1476
Nonclinical pharmacokinetics a ...... e methyltransferase inhibitor.
@en
P2093
Alejandra Raimondi
Angelos Dovletoglou
Aravind Basavapathruni
Carly A Therkelsen
Christina J Allain
Christine R Klaus
Edward J Olhava
Margaret Porter Scott
Mikel P Moyer
P2860
P304
P356
10.1002/BDD.1889
P577
2014-02-14T00:00:00Z